Operator: And we’ll take our next question from the line of Thomas Smith with SVB Securities. Please go ahead.
Unidentified Analyst: Hi, good afternoon. This is Brian Conley on for Tom. I believe you just responded to a question about Truveta, but just curious if there are any other gating factors or any other obstacles or challenging factors you’re encountering as you’re progressing the basket trials. Thanks.
Mitchell Gold: Yeah. Thanks Brian. No, I think the reason we put Truveta in place was to be proactive at the start of the study. These are things that you want to be in front of. I would say our traditional efforts are looking at let us exceed the trial and get started in terms of law I think because awareness on the targets and strong awareness in the space. And we have a great group of investigators that we have brought in. The reason we brought Truveta onboard is we want to ask – add it on probably one of the number one, do it at the beginning of the trial. And two, as we push into the Phase 2 study next year that’s clearly resulted in accelerated approval. We wanted the collaboration between us and Truveta to be kind of fully integrated, so we can leverage it as we move into these studies.
Unidentified Analyst: Great. Thanks so much.
Mitchell Gold: Thanks.
Operator: And we’ll take our next question from the line of Mark Breidenbach with Oppenheimer. Please go ahead.
Mark Breidenbach: Hey, good afternoon guys. Thanks for taking our questions. Just a quick couple from me. First on the Truveta collaboration. Have you any thoughts on what they’re getting in return for helping optimize enrollment of RUBY-3 and RUBY-4?
Mitchell Gold: I am sorry. I lost you one second. Can you say that one more time?
Mark Breidenbach: Yeah, sorry. What’s Truveta getting in return for helping you guys enroll in RUBY-3 and RUBY-4?
Mitchell Gold: Let me take in traditional services agreement. So there’s kind of a baseline fee that we pay them and then as they enroll a certain number of patients, they have certain objectives that they need to meet to be able to generate service fees and as a result of that. So, it’s not any direct measures on services security.
Mark Breidenbach: Okay. Got it. And with regard to the upcoming presentation at WCN from RUBY-1, is there anything in that presentation that we haven’t already seen? What’s kind of going to be the focus of that upcoming presentation next week?
Mitchell Gold: Our main goal is to – reader awareness we didn’t present there last year that I am sure you’re aware, but make sure that, just build awareness about the target and the molecule with that audience, as it will be updated Phase 1 data with regard to additional follow-up is some of the subjects. Although the general conclusions about change that you can tell us some of our preceding comments.
Mark Breidenbach: Okay. Got it. Maybe one last one for me. I know, you mention the 80 mg and 240 mg dosing cohorts in RUBY-3. Can you just comment on the dosing schedules and how those compare to, let’s say, if we use povetacicept as the closest equivalent or competing drug, how will the dosing schedules compare between your drug and RemeGen’s? Thank you.
